More Paths to PI3Kγ

Len Stephens*, Phillip Hawkins
The Babraham Institute, Cambridge, United Kingdom

In the huge collection of molecules that underpin mammalian biology, only a small number stand out as targets for drug development. PI3Kγ is one such molecule that has received substantial investments to assess whether inhibitors can be developed as potential therapeutics. Although many studies have addressed the structure and regulation of PI3Kγ, our understanding of the enzyme is far from complete. A publication in PLoS Biology from the Wymann group provides new insights into this process by identifying an alternate route to PI3Kγ activation, and these results enable us to understand how PI3Kγ signaling is regulated in mast cells and is thus important in so many cell, tissue, and disease settings.

Roles for PI3Kγ in Health and Disease

PI3Kγ is expressed strongly in a number of immune cells, including mast cells, neutrophils, and eosinophils. In these cell types, it sits at a key, early, near-receptor stage in pro-inflammatory, intracellular signaling pathways. This is, in part, why genetic loss or selective inhibition of PI3Kγ has little effect on normal mouse development and function but can suppress inflammation in a number of mouse models of disease, including rheumatoid arthritis [1], anaphylaxis [2], atherosclerosis [3], and glomerulonephritis [4]. Interestingly, however, PI3Kγ seems to perform a variety of important roles in other cell types/systems where it is often barely detectable—for example, in the heart, where it suppresses cAMP signaling and contractility (and hence may be a useful therapeutic target in certain types of cardiac failure) [3–7], and in fat metabolism, where its activity supports fat deposition [8]. Finally, there is evidence that PI3Kγ may support tumour growth and progression [9,10].

Class I PI3K Signaling

PI3Kγ (phosphoinositide 3-kinase) belongs to the class I PI3K family of signaling enzymes (along with PI3Ks α, β, and δ) that 3-phosphorylate the membrane phospholipid PtdIns(4,5)P2 to yield the signaling lipid PtdIns(3,4,5)P3. The class I PI3Ks can all be activated by cell surface receptors and function but can suppress inflammation in a number of mouse models of disease, including rheumatoid arthritis [1], anaphylaxis [2], atherosclerosis [3], and glomerulonephritis [4]. But the involvement of the p84 in PI3Kγ has been less clear. There is anecdotal evidence in the field that the interaction between p84 and p110γ is less tight than that between p101 and p110γ. Despite this, once bound, p84/p110γ complexes are able to survive gel-filtration chromatography or multiple cycles of washing with traditional detergent-containing lysis buffers through pull-down protocols without significant dissociation, suggesting that their association is not rapidly reversible. It is clear, however, that the p84/p110γ heterodimer is substantially less sensitive to Gβγs—The Detail

PI3Kγ is made up of a p110γ catalytic subunit [11] combined with either a p84 (also called p87 PIKAP) [12–14] or a p101 regulatory subunit [15]. Interestingly, the three proteins are well conserved in eukaryotes from humans to fish; p84 and p101 have even retained their neighbouring genetic location. PI3Kγ is thought to exist as a dimer in vivo, although this is only based on the lack of any evidence for the existence of free p110γ. It appears that despite immune cells like neutrophils, expressing p101 and p84, mast cells, the subject of the study reported by the Wymann group, only express p84 [16].

The p101 Regulatory Subunit

Our current understanding of PI3Kγ activation centers on how the p101 subunit allows the complex to be substantially activated by G-protein βγ subunits (Gβγs) liberated from G proteins upon activation of GPCRs. This mechanism is thought to explain why PI3Kγ is typically (but not universally) activated by GPCRs. Frustratingly, we do not know the residues/domains in either p101 or p110γ involved in the interaction with Gβγs. It appears the interaction between p101 and p110γ is very tight and unlikely to have a significant on/off rate under physiological conditions. There is some evidence supporting direct interactions between Gβγs and both p101 and p110γ [15,17].

The p84 Regulatory Subunit

But the involvement of the p84 in PI3Kγ has been less clear. There is anecdotal evidence in the field that the interaction between p84 and p110γ is less tight than that between p101 and p110γ. Despite this, once bound, p84/p110γ complexes are able to survive gel-filtration chromatography or multiple cycles of washing with traditional detergent-containing lysis buffers through pull-down protocols without significant dissociation, suggesting that their association is not rapidly reversible. It is clear, however, that the p84/p110γ heterodimer is substantially less sensitive to Gβγs—The Detail

Regulation by Ras

P110γ contains a classical Ras-binding domain (RBD) that has been demonstrated to bind selectively to Ras-GTP. Ras-GTP can...
activate p110γ, p101/p110γ, and p84/p110γ in vitro or in transfected cells [19]. Furthermore, this interaction is important in vivo, as demonstrated by the effect of knocking-in a Ras-insensitive, but Gβγ-sensitive, allele of p110γ in mice (p110γ<sup>p84α/p110γ</sup> [19]). There are lines of evidence which suggest that Ras-GTP (and not Gβγs) regulates p84/p110γ complexes in transfected cells, while p101/p110γ complexes are only regulated by Gβγs [18]. This view suggests that p84/p110γ complexes may be less exclusively controlled by GPCRs but rather by any ligand capable of activating Ras, including receptor tyrosine kinase pathways.

**Mast Cells**

Mast cells are tissue-resident immune cells that express high-affinity receptors for IgE (FcεRI). Mast cell FcεRI are effectively permanently bound with IgE. These FcεRI/IgE complexes are activated by ligands that are specific targets for the variable regions of IgEs, including allergens. Once activated, mast cells can release a huge range of inflammatory mediators, including histamine, LTB4, PAF, and PGD2. The intracellular signals generated by activated FcεRI are primarily based on protein tyrosine kinase–mediated mechanisms that would naturally lead to activation of the class IA PI3Ks such as PI3Kδ [21,22]; however, PI3Kγ has been shown to have an important role in mast cell activation [2]. The role for PI3Kγ is through an autocrine/paracrine mechanism, involving among other things released adenosine working back on A3 (A3-Ars) GPCRs, that synergizes with the primary effects of FcεRI activation.

**Insights into Mast Cell Regulation of PI3Kγ Activation**

A recent study by Walser et al. in *PLOS Biology* began with several threads, a key one of which was the ability of thapsigargin (a drug that causes a very selective receptor-independent increase in cytosolic Ca<sup>2+</sup> by slowly releasing intracellular ER Ca<sup>2+</sup> stores into the cytosol and activating Ca<sup>2+</sup> influx via the store-operated-Ca<sup>2+</sup>-entry (SOCE) route) to stimulate phosphorylation of PKB in a PI3Kγ-dependent manner. That result was very unexpected and a variety of controls suggested it was unlikely to be dependent on release of the mast cell paracrine/autocrine factor adenosine acting back on A3 GPCRs.

Wide-ranging experiments support a model (Figure 1) in which FcεRI cross-linking leads to a Ca<sup>2+</sup> signal, involving SOCE, that drives activation of PKCβ. Through an interaction between PKCβ and the helical domain of p110γ, S582-p110γ is phosphorylated. This leads to both activation of the kinase activity of PI3Kγ (which leads to increased PIP<sub>3</sub> and downstream signaling) and a reduction in the affinity of p110γ for p84. The outcome of these events is argued to be a rebalancing in the amount of GPCR-sensitive p84/p110γ and free, GPCR-insensitive p110γ, thus reducing the sensitivity of PI3Kγ to GPCRs. These conclusions represent major conceptual advances for the field. Beyond their major impact on our understanding of mast cell biology, they offer potential molecular explanations for the roles of PI3Kγ in a number of important, but ill-understood, physiological and disease settings. Furthermore, the paper introduces beautiful structural data from deuterium-exchange protection assays that reveal where the presence of p84 masks the surface of p110γ in its helical domain. Further biochemical experiments demonstrate the potential power of interactions with, or post translational

![Figure 1. Mast cell environment regulates PI3Kγ activation.](image-url)
modifications of, the helical domain of p110s to regulate class I PI3K function both in terms of changes in catalytic activity and binding of adaptor subunits. This type of mechanism may be a widely important mode of regulation in class I PI3K signaling.

As ever with first steps, many questions remain. The role of Ras in the activation of PI3Kγ in mast cells is unclear. Given that RasGrp1 (and RasGrp4) is relatively abundant in mast cells, and activated by a combination of PKC-mediated phosphorylation and diacylglycerol (DAG) binding, and in lymphocytes is the primary mechanism driving activation of Ras downstream of antibody receptor activation [23,24], it might have been expected to be involved in this pathway, but does not appear to be. This will be clarified by testing the impact of knocking-in a Ras-insensitive version of p110 on mast cell responsiveness. The apparent contradiction between the simple model described above and the dogma that p84 is tightly bound to p110γ (that is supported by the data from the deuterium-exchange protection assays) needs to be resolved. It currently leaves it difficult to understand the pattern of events; does PKCβ need to compete with p84 to enable significant stoichiometries of phosphorylation to occur? As always, a high-resolution view of the p84/p110γ complex would be immensely useful.

Concluding Remarks

The PLOS Biology paper from Walser et al. makes many important contributions. It reveals how intracellular signals from mast cell FceRI, classically thought to engage class IA PI3K signaling, can control p110γ directly via the PLC effectors Ca2+ and DAG/PKC. These effects are mediated by an interaction between PKCβ and the helical domain of p110γ that enables S502-p110γ to be phosphorylated and activate the lipid kinase activity of PI3Kγ. The outcome is the emergence of a new mechanism by which class I PI3Ks can be activated. The paper also provides a first insight into the interactions between p110γ and p84, hopefully the first step in the exploitation of deuterium-exchange methodologies to reveal more about the interactions of p101, p84, p110γ, and Gβγ. Finally, the work may offer molecular explanations for some of the many poorly understood roles that PI3Kγ fulfills outside of the immune system.

References

1. Campos M, Ruckle T, Ji H, Ardisone V, Rintelen F, et al. (2005) Blockade of PI3Kγ represses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11: 936–943.

2. Laffargue M, Calvez K, Finan F, Trifilieff A, Barbier M, et al. (2002) Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 16: 441–451.

3. Fougérat A, Gayral S, Gourdy P, Schambourg A, Ruckle T, et al. (2008) Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 117: 1310–1317.

4. Barber DF, Bartolome A, Hernandez C, Flores JM, Redondo C, et al. (2005) PI3Kgamma inhibition blocks glomerulosclerosis and extends lifespan in a mouse model of systemic lupus. Nat Med 11: 935–935.

5. Patracco E, Notte A, Barberis I, Selvettella G, Maffei A, et al. (2004) PI3K gamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 110: 375–387.

6. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, et al. (2002) PI3Kgamma in tumor growth and metastasis. Oncogene 31: 2350–2361.

7. Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, et al. (2011) Integrating signaling systems in B cells. Blood 105: 3648–3654.

8. Becattini B, Marone R, Zani F, Arsenijevic D, Seydoux J, et al. (2011) PI3Kgamma inhibition blocks glomerulosclerosis and extends lifespan in a mouse model of systemic lupus. Nat Med 11: 935–935.

9. Brazzatti JA, Klingler-Hoffmann M, Haylock-Jacobs S, Harata-Lee Y, Niu M, et al. (2012) Differential roles that PI3K regulatory subunits play in the allergic response. Nature 431: 1007–1011.

10. Edling CE, Selvaggi F, Buss R, Maffucci T, Di Sebastiano P, et al. (2010) Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 16: 4920–4927.

11. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, et al. (1995) Cloning and characterization of a G protein-activated human phosphoinositide-3-kinase. Science 269: 690–693.

12. Voigt P, Brock G, Nürnberg B, Schaefer M (2005) Assigning functional domains within the p101 regulatory subunit of phosphoinositide-3-kinase gamma. J Biol Chem 280: 5121–5127.

13. Voigt P, Dornier MB, Schaefer M (2006) Characterization of PI3Kδ kinase: a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PI3Kδ. J Biol Chem 281: 9977–9986.

14. Suire S, Coadwell J, Ferguson GJ, Davidson K, Haskin M, et al. (2005) p84, a new Gbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma. Curr Biol 15: 566–570.

15. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, et al. (1997) The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89: 105–114.

16. Behnam Meyer T, Marone R, Collmann E, Calvez K, Risch E, et al. (2009) PI3Kgamma adenosine receptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)3 pools in mast cells. Sci Signal 2: ra27.

17. Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, et al. (2011) Integrating cardiac PI3K and CaM signaling through a PKA anchoring function of p110gamma. Mol Cell 42: 84–95.

18. Becattini B, Marone R, Zani F, Arsenijevic D, Seydoux J, et al. (2011) PI3Kgamma within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proc Natl Acad Sci U S A 108: E554–E563.

19. Buus R, Maffucci T, Di Sebastiano P, et al. (2005) PI3Kgamma inhibition blocks glomerulosclerosis and extends lifespan in a mouse model of systemic lupus. Nat Med 11: 935–935.